Biofrontera(us:BFRI)

    1.02

    +4.24%

    Updated on 2024-12-23

    Open:0.9800
    Close:1.02
    High:1.03
    Low:0.9720
    Pre Close:0.9785
    Volume:248547.00
    Amount:249953.41
    Turnover:3.20%
    Shares:7.76M
    MarketCap:7.96M
    DateTotalTotal SharesTotal RatioNewIncreasedDecreased
    2024-06-3015116907522.95%433
    2024-03-3114108586121.34%605
    2023-12-311194580.62%323
    2023-09-3016162291.19%339
    2023-06-3017397140.15%1110
    2023-03-31188493403.18%453
    2022-12-31187955702.98%267
    2022-09-30208537733.63%547
    dateorgNametotalratiochangeShareschangeRatio
    2024-03-31Rosalind Advisors, Inc.5042619.91%504261
    2024-03-31Aigh Capital Management Llc5014349.85%501434
    2024-03-31Scotia Capital Inc.400000.79%40000
    2024-03-31Xtx Topco Ltd121850.24%12185
    2024-03-31Hrt Financial Lp106390.21%10639
    2024-03-31Renaissance Technologies Llc102210.20%10221
    2024-03-31Blackrock Inc.46220.09%0
    2024-03-31Tower Research Capital Llc (Trc)19050.04%-1268-39.96%
    2024-03-31Osaic Holdings, Inc.5760.01%-33-5.42%
    2024-03-31Royal Bank Of Canada110.00%0

    About

    Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.
    Address:120 Presidnetial Way,Suite 330

    Market Movers